Clinical News: Page 36

ARRS: 'Neurotheranostics' may be new frontier for nuclear medicine
By Will Morton
Advances in brain PET imaging combined with new treatments for Alzheimer’s have given rise to a new concept of "neurotheranostics."
April 29, 2025
A conceptual framework for neurotheranostics.
ARRS: Most women OK with mammo data used to assess cancer risk
By Amerigo Allegretto
Most women are comfortable with having their mammogram data be used to calculate lifetime breast cancer risk
April 28, 2025
Mammogram Breast
ARRS: MASLD diagnosis may be subject to racial factors
By Kate Madden Yee
The diagnosis of metabolic-associated steatotic liver disease (MASLD) may be influenced by ethnic, racial, and social factors.
April 28, 2025
Liver Disease Stages
Week in Review: Right to repair in NC | LCS for nonsmokers | Do women want mammo AI?
By Erik L. Ridley
Our most highly viewed articles last week included coverage of a right-to-repair bill for imaging equipment and the potential benefit of lung cancer screening for nonsmokers.
April 26, 2025
Mammo uptake among veterans on par with nonveterans
By Amerigo Allegretto
Female veterans are as likely to undergo screening mammography as nonveteran women.
April 25, 2025
Mammogram Patient
SPECT/CT predicts overall survival in Pluvicto patients
By Will Morton
New evidence supports using SPECT/CT scans along with serum PSA levels to evaluate early patient responses to Pluvicto treatment.
April 25, 2025
Patient examples of SPECT/CT and PET/CT RECIP 1.0. (A) SPECT and PET maximum-intensity projection (MIP) images in 74-year-old man with mCRPC. Serum PSA level at baseline was 449 ng/mL and slightly increased to 525 ng/mL after two cycles of Lu-177 PSMA. Eastern Cooperative Oncology Group (ECOG) score was 2 at baseline and increased to 3 after 2 cycles. The patient was classified by readers as RECIP-progressive disease on both SPECT and PET. Overall survival was 4.7 months. Two cycles of Lu-177 PSMA were administered. (B) SPECT and PET MIP images in 74-year-old man with mCRPC. Serum PSA level was 231 ng/mL at baseline and decreased to 12.5 ng/mL after 2 cycles of Lu-177 PSMA. ECOG score was less than 2 at baseline and after 2 cycles of Lu-177 PSMA. The patient was classified by readers as RECIP-partial response on both SPECT and PET. Overall survival was 14.3 months. Four cycles of Lu-177 PSMA were administered.
AI-assisted brain MRI shows promise for improved glioma care
By Kate Madden Yee
An AI-based technique used to analyze brain MRI exams taken of children with gliomas shows promise for predicting recurrence.
April 25, 2025
Glioma Letters Brain
Deep-learning technique boosts diagnostic ability of fast knee MRI
By Kate Madden Yee
A new, fast deep learning-based MR imaging technique shows excellent performance for diagnosing knee injuries, researchers have reported.
April 24, 2025
2025 04 23 Ajr Vosshenrich Thumbnail
PET scans identify people at early risk for cognitive decline
By Will Morton
Amyloid PET scans in people with early signs of Alzheimer’s can identify those at higher risk of progressing to cognitive decline.
April 24, 2025
Ad Voxels Thumbnail
Most veterans adhere to post-EVAR surveillance imaging
By Amerigo Allegretto
Adherence to surveillance imaging after endovascular abdominal aortic aneurysm repair (EVAR) is high among veterans.
April 24, 2025
Heart Valves 3 D Base Thumbnail
Quantitative CT textures of the lung help assess COPD severity
By Kate Madden Yee
Quantitative CT can capture lung inflammation patterns to assess the severity of chronic obstructive pulmonary disease (COPD).
April 23, 2025
Copd
ACS: Breast cancer screening rates have recovered post-COVID
By Kate Madden Yee
Rates of up-to-date breast cancer screening have recovered after declining during the COVID-19 pandemic.
April 23, 2025
Breast Screening Mammo
Previous Page
Page 36 of 3671
Next Page